Dose-dependent severe cutaneous reactions to imatinib

The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ugurel, Selma (VerfasserIn) , Hildenbrand, Ralf (VerfasserIn) , Schadendorf, Dirk (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 15 April 2003
In: British journal of cancer
Year: 2003, Jahrgang: 88, Heft: 8, Pages: 1157-1159
ISSN:1532-1827
DOI:10.1038/sj.bjc.6600893
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.bjc.6600893
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/6600893
Volltext
Verfasserangaben:S. Ugurel, R. Hildenbrand, E. Dippel, A. Hochhaus and D. Schadendorf
Beschreibung
Zusammenfassung:The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutaneous reactivity pattern different from allergic hypersensitivity.
Beschreibung:Gesehen am 18.11.2020
Beschreibung:Online Resource
ISSN:1532-1827
DOI:10.1038/sj.bjc.6600893